HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept

A wide gap exists between what Patrick Soon-Shiong says his cancer drugs can achieve and what they actually do, STAT's Adam Feuerstein writes.

By STAT News · Jun 18, 2026 · via STAT News
STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
The WeekFiercePharma ↗
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treat…
Jun 18, 2026
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
The WeekFierceBiotech ↗
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-infer…
Jun 18, 2026
FDA signals openness to Moderna flu shot; UniQure and Lilly make moves
The WeekBriefing
Regulators appear receptive to Moderna's flu vaccine, UniQure prepares a Huntington's filing, and Lilly announ…
Jun 18, 2026